radiolabelling

R&D

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.